“We have enrolled COVID-19 patients in a research study to examine their host transcriptional responses over time. From this data we will design drug targets and develop and test with in vivo models. Our team (consisting of 30 scientists) has expertise in coronaviruses, RNA-Seq methods, drug design, building therapeutic platforms, and SARS-CoV-2 mouse models. We have been openly and collaboratively analyzing publicly available transcriptome data from COVID-19 patients in Wuhan, China (https://osf.io/7nrd3/). We understand the importance of a solid experimental design for sample collection, as well as the value of sound data analysis methods and open collaborations with coronavirus and medical subject matter experts when interpreting results and inferring host infection dynamics for SARS-CoV-2. Our study will…”